Semin intervent Radiol 2017; 34(02): 187-200
DOI: 10.1055/s-0037-1602710
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Therapeutic Ultrasound and Prostate Cancer

Karthik M. Sundaram
1  Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
,
Sam S. Chang
2  Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
,
David F. Penson
2  Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
,
Sandeep Arora
1  Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
2  Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
› Author Affiliations
Further Information

Publication History

Publication Date:
01 June 2017 (online)

Abstract

Therapeutic ultrasound approaches including high-intensity focused ultrasound (HIFU) are emerging as popular minimally invasive alternative treatments for localized, low-to-intermediate risk prostate cancer. FDA approval was recently granted for two ultrasound-guided HIFU devices. Clinical trials for devices using MRI guidance are ongoing. The current level of evidence for whole-gland ultrasound ablation suggests that its clinical efficacy and adverse event rates including erectile dysfunction and urinary incontinence are similar to current definitive therapies such as radical prostatectomy and external-beam radiotherapy. Short-term data suggest that more focal therapy could reduce the rates of adverse events.